AstraZeneca: Diabetes Mellitus, Type 1 trials
The registry lists 18 Diabetes Mellitus, Type 1 studies with AstraZeneca as lead sponsor. 0 are open to participants now and 9 have results posted.
Phase 1 4Phase 2 5Phase 3 8No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DMCompletedNCT02582840Phase 1Results posted
- The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DMCompletedNCT02582814Phase 3Results posted
- Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes MellitusCompletedNCT02500979Phase 1Results posted
- Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 DiabetesCompletedNCT02460978Phase 3Results posted
- Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 DiabetesCompletedNCT02268214Phase 3Results posted
- BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 DiabetesCompletedNCT01498185Phase 2Results posted
- Diabetic Retinopathy Candesartan TrialsCompletedNCT00252733Phase 3Results posted
- DIabetic Retinopathy Candesartan Trials.CompletedNCT00252720Phase 3Results posted
- An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 DiabetesCompletedNCT00229658Results posted
- Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DMCompletedNCT01708044Phase 1
- To Evaluate the Bioavailability of a Tablet of AZD1656CompletedNCT00817505Phase 1
- A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes MellitusCompletedNCT00313183Phase 2
- Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes MellitusCompletedNCT00108004Phase 3
- Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes MellitusCompletedNCT00107107Phase 3
- Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I DiabetesCompletedNCT00064714Phase 2
- Evaluation of the Effect of Pramlintide on Satiety and Food IntakeCompletedNCT00042601Phase 2
- Evaluation of the Bioavailability of PramlintideCompletedNCT00042471Phase 2
- Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose ControlCompletedNCT00042458Phase 3